TSE:CPH Cipher Pharmaceuticals - CPH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. C$3.35 +0.01 (+0.30%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's RangeC$3.30▼C$3.4650-Day RangeC$3.34▼C$3.8752-Week RangeC$2.00▼C$4.07Volume39,754 shsAverage Volume13,343 shsMarket CapitalizationC$84.02 millionP/E Ratio7.28Dividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesSocial Media About Cipher Pharmaceuticals (TSE:CPH) StockCipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.Read More Receive CPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPH Stock News HeadlinesMarch 19, 2023 | seekingalpha.comCipher Pharmaceuticals Non-GAAP EPS of -$0.12March 16, 2023 | finance.yahoo.comCipher Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 24, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 1, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Closing of New US$35 Million Credit FacilityDecember 21, 2022 | seekingalpha.comCPH:CA Cipher Pharmaceuticals Inc.December 4, 2022 | finance.yahoo.comCipher Pharmaceuticals Inc.'s (TSE:CPH) Stock Is Going Strong: Have Financials A Role To Play?November 13, 2022 | finance.yahoo.comCipher Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagSeptember 14, 2022 | baystreet.caSigna, Boardwalktech, Cipher at 52-Week HighsMarch 24, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.August 5, 2022 | finance.yahoo.comCipher Pharmaceuticals Schedules Q2 2022 Earnings Release and Conference CallJune 22, 2022 | finance.yahoo.comCipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders and Thanks Director Dr. John MullMarch 17, 2022 | finance.yahoo.comCipher Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial ResultsNovember 11, 2021 | finance.yahoo.comCipher Announces Third Quarter and Year-to-Date 2021 Financial ResultsNovember 3, 2021 | finance.yahoo.comCipher Pharmaceuticals Schedules Q3 2021 Earnings Release and Conference CallOctober 19, 2021 | finance.yahoo.comInvesting in Cipher Pharmaceuticals (TSE:CPH) a year ago would have delivered you a 155% gainSeptember 8, 2021 | finance.yahoo.comCipher Pharmaceuticals Announces Renewal of Normal Course Issuer BidAugust 12, 2021 | finance.yahoo.comCipher Reports 30% Revenue Growth and 40% Adjusted EBITDA Growth in Second Quarter of 2021, Driven by Strength in Epuris and AbsoricaAugust 9, 2021 | ca.finance.yahoo.comStocks in play: Cipher Pharmaceuticals Inc.June 23, 2021 | finance.yahoo.comCipher Pharmaceuticals Reports Voting Results From Annual Meeting of ShareholdersMay 14, 2021 | markets.businessinsider.comCipher Pharmaceuticals Reports First Quarter 2021 Financial ResultsMay 5, 2021 | finance.yahoo.comCipher Pharmaceuticals Schedules Q1 2021 Earnings Release and Conference CallApril 2, 2021 | finance.yahoo.comCipher Pharmaceuticals Inc.'s (TSE:CPH) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?March 18, 2021 | markets.businessinsider.comCipher Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial ResultsJanuary 16, 2021 | benzinga.comCipher Pharmaceuticals Receives Arbitration Award on Trulance®January 7, 2021 | wsj.comCipher Pharmaceuticals Inc.December 3, 2020 | marketwatch.comOutlook on the Acne Drugs Global Market to 2025 - Impact Analysis of COVID-19November 10, 2020 | marketwatch.comActinic Keratosis Treatment Market Forecast Revised in a New FMI Report as COVID-19 Projected to Hold a Massive Impact on Sales in 2028See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPH Company Calendar Today3/24/2023Next Earnings (Estimated)5/11/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:CPH Previous SymbolTSE:DND CUSIPN/A CIKN/A Webwww.cipherpharma.com Phone+1-905-6025840FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C$0.46 Trailing P/E Ratio7.28 Forward P/E Ratio8.93 P/E GrowthN/ANet IncomeC$26.64 million Net Margins128.83% Pretax MarginN/A Return on Equity51.73% Return on Assets11.01% Debt Debt-to-Equity Ratio0.67 Current Ratio4.07 Quick Ratio2.67 Sales & Book Value Annual SalesC$20.68 million Price / Sales4.06 Cash FlowC$0.95 per share Price / Cash Flow3.53 Book ValueC$2.56 per share Price / Book1.31Miscellaneous Outstanding Shares25,080,000Free FloatN/AMarket CapC$84.02 million OptionableNot Optionable Beta1.02 Key ExecutivesMr. Craig J. MullInterim CEO & ChairmanDr. Diane GajewczykVP of Scientific & Medical AffairsMr. Bryan JacobsChief Financial OfficerMr. Emilio PrestiDirector of Sales, Marketing & Hospital Bus.Chuoru LiCorp. ControllerDavid MillerDirector of Fin.More ExecutivesKey CompetitorsBioSyentCVE:RXDelta 9 CannabisCVE:NINEGreen Organic DutchmanTSE:TGODHEXOTSE:HEXOWeedMDCVE:WMDView All CompetitorsInsidersChristian GodinSold 4,000 sharesTotal: C$15,600.00 ($3.90/share)Christian GodinSold 5,000 sharesTotal: C$18,500.00 ($3.70/share)View All Insider Transactions CPH Stock - Frequently Asked Questions Should I buy or sell Cipher Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPH shares. View CPH analyst ratings or view top-rated stocks. How have CPH shares performed in 2023? Cipher Pharmaceuticals' stock was trading at C$3.84 at the beginning of 2023. Since then, CPH shares have decreased by 12.8% and is now trading at C$3.35. View the best growth stocks for 2023 here. When is Cipher Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our CPH earnings forecast. What other stocks do shareholders of Cipher Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Bellatrix Exploration (BXE), Aurora Cannabis (ACB), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Ampio Pharmaceuticals (AMPE), Catalyst Biosciences (CBIO), Crescent Point Energy (CPG) and Enbridge (ENB). What is Cipher Pharmaceuticals' stock symbol? Cipher Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CPH." How do I buy shares of Cipher Pharmaceuticals? Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Cipher Pharmaceuticals' stock price today? One share of CPH stock can currently be purchased for approximately C$3.35. How much money does Cipher Pharmaceuticals make? Cipher Pharmaceuticals (TSE:CPH) has a market capitalization of C$84.02 million and generates C$20.68 million in revenue each year. The company earns C$26.64 million in net income (profit) each year or C$0.46 on an earnings per share basis. How can I contact Cipher Pharmaceuticals? Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The official website for the company is www.cipherpharma.com. The company can be reached via phone at +1-905-6025840. This page (TSE:CPH) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.